News Releases

scPharmaceuticals Provides Business Update
BURLINGTON, Mass. --(BUSINESS WIRE)--Oct. 8, 2020-- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today provided a business update[…]
scPharmaceuticals Hosting Key Opinion Leader Call on FUROSCIX® (furosemide) for subcutaneous administration
FUROSCIX ® is currently under development for the treatment of congestion due to fluid overload in adult patients with worsening heart failure who display reduced responsiveness to oral diuretics and who do not require hospitalization Call on Tuesday, September 29, 2020 at 11am Eastern Time[…]
scPharmaceuticals to Participate in Two Upcoming Investor Conferences
BURLINGTON, Mass. --(BUSINESS WIRE)--Sep. 3, 2020-- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today[…]
scPharmaceuticals Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update
Preparations ongoing for December 30, 2020 FUROSCIX ® PDUFA date BURLINGTON, Mass. --(BUSINESS WIRE)--Aug. 13, 2020-- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused[…]
scPharmaceuticals Announces FDA Acceptance of FUROSCIX® New Drug Application Resubmission
FDA sets PDUFA date of December 30, 2020 BURLINGTON, Mass. --(BUSINESS WIRE)--Jul. 27, 2020-- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient[…]
scPharmaceuticals Appoints Sara Bonstein to Board of Directors
BURLINGTON, Mass. --(BUSINESS WIRE)--Jul. 10, 2020-- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today[…]
scPharmaceuticals Announces FUROSCIX® NDA Resubmission
BURLINGTON, Mass. --(BUSINESS WIRE)--Jul. 1, 2020-- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today[…]
scPharmaceuticals Announces New Presentation Time for BMO’s Virtual 2020 Prescriptions for Success Healthcare Conference
BURLINGTON, Mass. --(BUSINESS WIRE)--Jun. 18, 2020-- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today[…]
scPharmaceuticals Inc. to Present at Upcoming Investor Conferences
BURLINGTON, Mass. --(BUSINESS WIRE)--May 28, 2020-- scPharmaceuticals Inc. (Nasdaq:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today[…]
scPharmaceuticals Announces Pricing of Public Offering of Common Stock
BURLINGTON, Mass. --(BUSINESS WIRE)--May 20, 2020-- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today[…]
scPharmaceuticals Inc. Announces Proposed Underwritten Public Offering of Common Stock
BURLINGTON, Mass. --(BUSINESS WIRE)--May 20, 2020-- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today[…]
scPharmaceuticals Inc. Reports First Quarter 2020 Financial Results and Provides Business Update
Remain on track to resubmit FUROSCIX® NDA with the FDA by mid-year 2020 Strong balance sheet with over $75M in cash Projected annual loss for 2020 narrows to $36-40M BURLINGTON, Mass. --(BUSINESS WIRE)--May 12, 2020-- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on[…]
scPharmaceuticals Inc. Reports Fourth Quarter and Year Ended 2019 Financial Results and Provides Business Update
Remain on track to resubmit FUROSCIX ® NDA with the FDA by mid-year 2020 Initiating FUROSCIX pre-commercialization and product positioning efforts Strong balance sheet; ending 2019 with $72.8 million in cash Guiding 2020 quarterly GAAP expenses of $9.0 to $11.0 million BURLINGTON, Mass.[…]
scPharmaceuticals Inc. to Present at the Cowen and Company’s 40th Annual Health Care Conference
BURLINGTON, Mass. --(BUSINESS WIRE)--Feb. 26, 2020-- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs, today[…]
scPharmaceuticals Inc. to Present at the 9th Annual SVB Leerink Global Healthcare Conference
BURLINGTON, Mass. --(BUSINESS WIRE)--Feb. 20, 2020-- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs, today[…]